Kornimate/medical-research-clean huggingface dataset:
identification of specific molecular signatures in pediatric, adolescent, and young adult rhabdomyosarcoma through spatial proteome analysis using mass spectrometry

Conditions: Rhabdomyosarcoma

Summary: this non-interventional study aims to develop spatial proteomics for analyzing small ffpe tumor samples in rhabdomyosarcoma. it will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.

this is a non-interventional, monocentric, retrospective cohort study aimed at developing a spatial proteomics analysis method for small tumor samples (ffpe) to precisely characterize proteins at the tissue level in rhabdomyosarcoma (rms). using mass spectrometry, the study will identify molecular signatures associated with different tumor regions, histological subtypes, patient survival, and treatment resistance. the goal is to identify potential protein biomarkers and therapeutic targets. data from clinical samples will be analyzed to find biomarkers correlated with survival and resistance to treatment. no patient intervention is required, as the study uses pre-existing biological samples and clinical data.

Eligibility criteria:
inclusion criteria: * age between 0 and 25 years at the time of initial diagnosis * diagnosis of rhabdomyosarcoma confirmed histologically * care at the oscar lambret center between january 2005 and november 2024 * no objection to the re-use of data and biological samples collected as part of care for research activities. exclusion criteria: * unavailability of biological sample in ffpe from biopsy and/or surgical specimen for diagnosis at centre oscar lambret; * patient under guardianship or trusteeship.

Keywords: rhabdomyosarcoma molecular signatures spatial proteome targeted therapy
radiolabeled folic acid and imaging to detect ovarian cancer

Conditions: Ovarian Cancer

Summary: rationale: diagnostic procedures using the drug radiolabeled folic acid and imaging may be effective in detecting ovarian cancer. purpose: diagnostic trial to study the effectiveness of radiolabeled folic acid plus imaging in detecting ovarian cancer.

objectives: i. evaluate the effectiveness of folic acid conjugated with indium in 111 to diagnose ovarian cancer and locate metastatic disease. outline: this is a diagnostic study. patients receive an injection of folic acid conjugated with indium in 111. the patient then undergoes imaging studies at various time points (e.g., 1, 4, and 24 hours). patients then undergo exploratory surgery, the results of which are then compared to the imaging studies. projected accrual: a total of 30 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: suspected ovarian cancer or recurrence of ovarian cancer scheduled for exploratory surgery patient characteristics: age: 18 and over performance status: zubrod 0-2 life expectancy: not specified hematopoietic: wbc at least 3000/mm3 granulocyte count at least 1500/mm3 platelet count at least 100,000/mm3 hemoglobin at least 9 g/dl hepatic: bilirubin no greater than 2.0 mg/dl sgpt and sgot no greater than 2 times upper limit of normal (uln) alkaline phosphatase no greater than 2 times uln no acute hepatitis renal: creatinine no greater than 1.4 mg/dl bun no greater than 1.5 times uln no known or suspected kidney disease cardiovascular: no history of congestive heart failure no unstable angina no myocardial infarction within 6 months other: not pregnant or nursing no septicemia or severe infection no medical condition that would preclude the administration of large fluid volumes over a short period of time prior concurrent therapy: biologic therapy: not specified chemotherapy: at least 3 months since prior cytotoxic chemotherapy endocrine therapy: not specified radiotherapy: at least 3 months since prior radiotherapy surgery: see disease characteristics other: at least 2 days since prior folic acid supplements at least 5 days since nonsteroidal antiinflammatory medications

Keywords: stage i ovarian epithelial cancer stage ii ovarian epithelial cancer stage iii ovarian epithelial cancer stage iv ovarian epithelial cancer recurrent ovarian epithelial cancer ovarian stromal cancer stage i ovarian germ cell tumor stage ii ovarian germ cell tumor stage iii ovarian germ cell tumor stage iv ovarian germ cell tumor recurrent ovarian germ cell tumor borderline ovarian surface epithelial-stromal tumor ovarian sarcoma
efficacy & safety study of yh22162 vs telmisartan/amlodipine in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment

Conditions: Hypertension

Summary: to evaluate efficacy and safety of yh22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment


Eligibility criteria:
inclusion criteria: * signed informed consent * men and women ≥ 19 years of age * essential hypertensive patients 1. if already taking antihypertensive drugs, mean sitting systolic blood pressure (mssbp) must be 140 mmhg ≤ mssbp \< 200 mmhg 2. if not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic blood pressure (mssbp) must be 160 mmhg ≤ mssbp \< 200 mmhg exclusion criteria: * patients with known or suspected secondary hypertension * other exclusions applied
development of an effective home-based-exercise-strategy

Conditions: Osteoarthritis, Hip; Total Hip Arthroplasty

Summary: osteoarthritis is one of the most common chronic diseases of the musculoskeletal system in elderly. patients with osteoarthritis experience pain, stiffness and loss of mobility. due to ageing western societies in the coming decades the number of elderly with osteoarthritis will progressively increase. osteoarthritis is a common indicator for a total hip arthroplasty (tha). a hip replacement is one of the most successful orthopedic surgeries. however, with regard to the postoperative rehabilitation a lot can be improved. the current situation after a tha is that physical therapy in the netherlands is not prescribed by default. patients are resigned from the hospital and receive home exercises. however, it is not clear whether patients actually carry out these exercises and whether they perform the exercises correctly.


Eligibility criteria:
inclusion criteria: * aged between 18 and 75 years * living independent * waiting for tha at either the martini hospital groningen or the medical centre leeuwarden in the netherlands exclusion criteria: * revision surgery * medical conditions that disallow independent living * cognitive impairment * inability to sufficiently read and understand dutch * participating in another rehabilitation program

Keywords: total hip arthroplasty physiotherapy osteoarthritis usual care home-based rehabilitation program
safety and effectiveness of artemisinin-based combination therapies (acts) with repeated treatments for uncomplicated falciparum malaria over a three-year period

Conditions: Malaria

Summary: a community-based, open-label, cluster-randomised longitudinal study in which children are randomized according to village health worker catchment areas comparing the safety and effectiveness of repeated treatments with artemether-lumefantrine (al) over a 3-year period in children 4-48 months to that of repeated treatment with dihydroartemisinin-piperaquine (dha-ppq).


Eligibility criteria:
inclusion criteria 1. aged between 4 months and 11 months at the time of randomization 2. bodyweight ≥ 5 kg at the time of randomization 3. provision of informed consent by parent or guardian 4. intention to stay in the study area for the time of the study exclusion criteria 1. ongoing participation into another clinical study involving ongoing or scheduled treatment with medicinal products 2. intent to reside outside of catchment area during the course of the study 3. known hypersensitivity to the study drug randomized to 4. known pre-existing hearing problem or neurological impairment 5. known need at the time of randomization for concomitant prohibited medication 6. suspected non-compliance with the follow-up schedule
is hip range of motion relevant in the treatment of chronic low back pain?

Conditions: Chronic Low-back Pain

Summary: the study will be carried out at the faculty of nursing and physiotherapy of the university of alcalá. the study has been approved by the animal research and experimentation ethics committee of the university of alcalá. a total of 60 subjects aged between 18 and 35 with non.specific low back pain will be selected and randomized in two interventions. the control group will carry out a specific strengthening program for the gluteus maximus and the experimental group will carry out the same strengthening program in addition to receiving a specific manual therapy program for both hips. the total duration of the treatments will be 8 weeks, with on-treatment evaluations at 4 and 8 weeks, with a follow-up after 1 month. the objective will be to determine the efficacy of manual therapy on the coxofemoral joint together with a protocol of gluteus maximus strengthening exercises in patients with non-specific chronic low back pain, in comparison with the same protocol of gluteus maximus strengthening exercises performed in isolation, in patients with non-specific chronic low back pain.

detailed description has not been entered.

Eligibility criteria:
inclusion criteria: * patients with non-specific low back pain, with a score of more than 2 on the visual analogue scale. * pain with a course of more than 12 weeks, of a chronic nature. exclusion criteria: * patients with neurological signs and symptoms or severe psychiatric illnesses. * subjects with a history of severe trauma, fracture or previous surgery on the lumbar spine or hip. * subjects with a history of musculoskeletal and/or rheumatologic disease. * patients with low back pain attributable to dysmenorrhoea. * pregnant patients. * individuals with fibromyalgia, autoimmune disorders. * subjects with a history of oncological processes.

Keywords: hip joint gluteus maximus manual therapy
investigating telmisartin study

Conditions: Covid19

Summary: this study will enroll 40 inpatients hospitalized for covid-19 at queens' medical center. participants will be randomized 1:1 to telmisartan (80 mg) vs placebo to be administered orally once daily x 21 days.

the study is intended to assess, in a pilot study, the effect of telmisartan in mitigating the severity of covid-19 related disease in hospitalized patients. data on clinical course and lab values will be passively abstracted from queen's standard of care evaluations on covid-19 in-patients. participants will be monitored closely as an outpatient if/when discharged prior to day 21. the only study-specific procedure will be a blood draw of ten (10) cc to be collected for research purposes at entry and at day 4 and day 21 of study for the evaluation of the renin-angiotensin system (ras) system and for various blood biomarkers of organ function/coagulation, inflammation, leukocyte chemotaxis, tissue remodeling/fibrosis and immune exhaustion.

Eligibility criteria:
inclusion criteria: * able to provide written informed consent prior to initiation of any study procedures. * within 72 hours of initial hospitalization for acute covid-19 disease management * male or non-pregnant female adult ≥18 years of age at time of enrolment. * able to easily swallow pills exclusion criteria: * systolic blood pressure less than 100 mmhg * self-reported history of decompensated liver failure * pregnancy or breast feeding * allergy to the study medication * current use of arb, ace inhibitors, or angiotensin receptor/neprilysin inhibitors (arnis). blood pressure medications in other classes will be permitted as long as the systolic bp is \>100 mmhg * currently receiving vasopressors for hypotension * prior reaction or intolerance to arb, ace inhibitor or anri for whom study participation would not be advisable in the opinion of the study team * current use of and on-going need for aliskiren, lithium, digoxin, and potassium sparing diuretics such as spironolactone * participating in other drug clinical trials except for other covid-19 treatment trials which will be allowed with the permission of the corresponding pi or co-pi and concurrence of the treating physician/hospitalist * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 10x upper limit of normal (uln) within 24 hours of baseline * absolute neutrophil count (anc) \< 1000/ml within 24 hours of baseline * platelet count \< 50,000/ml within 24 hours of baseline. * patients with acute kidney injury (aki) or chronic kidney disease (ckd) including individuals on hemodialysis may be enrolled based on the investigator's clinical judgement. * any serious medical condition/ abnormality or other issues that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study or suggests that the study is not in the patient's best interest * in the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
the effect of vitamin d supplementation in type 2 diabetes

Conditions: DIABETES MELLITUS

Summary: in many observational studies, vitamin d deficiency is related to glucose intolerance and diabetes. but there little randomized, controlled interventional studies that evaluate the effect of vitamin d in type 2 diabetes. investigators investigate the effect of high dose (2000iu) 25-hydroxy vitamin d on type 2 diabetes in glycemic controls, non-alcholic fatty liver disease, and arterial stiffness, and bone turnover markers.

after informed consent, investigators randomized 180 type 2 diabetes into interventiona group (25-hydroxy vitamin d 2000 iu+ elemental calcium 200mg per day) or placebo group (elemental calcium 200mg per day). the participants should control diabetes by oral medications or lifestyle intervention at the intervention period. investigators exclude the participants who took vitamin d or calcium or anti-osteoporotic drugs. investigators also exclude renal insufficiency (cr\>1.5 in men or cr\>1.4 in women) or heavy alcoholics. investigators followed the participants for 24 weeks. after randomization, investigators checked hba1c,glucose, calcium, 25-hydroxyvitamin d, ast, alt,creatinine, parathyroid hormone, bone-specific alkaline phosphatase, serum ctx, brachial-ankle pulse wave velocity, central blood pressure, and aortic augmentation index, and precontrast liver computed tomography. also investigators checked body weight, height, and peripheral blood pressure. at 12 weeks, investigators checked hba1c, 25-hydroxy vitamin d, ast, alt, calcium, and creatinine. at the end of the study(at 24 weeks), investigators checked hba1c, glucose, ast, alt, creatinine, calcium, bone-specific alkaline phosphatase, serum ctx, brachial-ankle pulse wave velocity, central blood pressure, aortic augmentation index, and precontrast liver computed tomography. after the study completed, investiators compared the data of interventional groups and placebo groups.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus patients who control glucose by oral antibiabetic drugs or lifestyle only * did not change antidiabetic drug before the study for 2 months * normal physical activity * 30 to 69 years * \>=6.5% or \<8.0% of hba1c exclusion criteria: * creatinine\>1.5 in men, \>1.4 in women * heavy alcoholics * who took calcium or vitamin d or anti-osteoporosis drug within 3 months before the study

Keywords: diabetes mellitus vitamin d arterial stiffness fatty liver bone turnover
dual reinforcement contingency management for alcohol use disorders

Conditions: Alcohol Use Disorder; Contingency Management

Summary: phosphatidylethanol (peth) is a direct biomarker of alcohol that can detect moderate to heavy drinking with high sensitivity and specificity over 3-week periods. reinforcing negative peth results alongside attendance may increase the proportion of participants who respond to cm during and post treatment. in the proposed study, the investigators will collect peth samples every 3 weeks for 12 weeks in 150 participants initiating outpatient treatment for alcohol use disorders. using a two-group randomized design, participants will be assigned to standard care with peth monitoring alone or with cm for attending treatment and submitting peth negative samples. compared to standard care and monitoring, the investigators expect that the cm intervention will result in greater attendance, more peth negative samples, and higher proportions of self-reported non-drinking days, along with lower proportions of heavy drinking days, over the short term and the long term, measured throughout a 12-month follow-up. the investigators anticipate that the reinforcement intervention may decrease other drug use and sexual risk behaviors that spread hiv, reduce psychiatric symptoms, and improve quality of life as well.


Eligibility criteria:
inclusion criteria: * in intensive outpatient treatment * dsm-5 diagnosis of an alcohol use disorder exclusion criteria: * have a condition that may hinder study participation
romiplostim in chemotherapy-induced thrombocytopenia

Conditions: Chemotherapy-induced Thrombocytopenia; Solid Malignancy

Summary: prospective interventional randomized controlled trial to assess safety and efficacy of romiplostim in chemotherapy-induced thrombocytopenia in children and adolescents with solid malignancy

chemotherapy-induced thrombocytopenia (cit) frequently complicates cancer treatment causing delays in treatment and dose reduction for subsequent administration of cancer-directed treatment. romiplostim is a potential agent that can improve platelet counts, allowing the resumption of chemotherapy, decreasing the need for platelet transfusions, and increasing the nadir platelet counts thus improving dose intensity.

Eligibility criteria:
inclusion criteria: age: 1- 18 years. patients diagnosed with solid malignancy based on clinical, histopathological features, and /or immunohistochemical staining. patients with chemotherapy-induced thrombocytopenia defined as either * severe thrombocytopenia either clinically with high bleeding score or laboratory by platelet count reaching critical level \< 20x10e9/l requiring platelet transfusion at time of chemotherapy cycle nadir. * delayed recovery of platelet count: a platelet count of less than 100 x10e9/l for 3 weeks from the first day of chemotherapy cycle administration or the previous dose was reduced by \>20% due to low platelet count \<100×10e9/l. exclusion criteria: * patients with second primary neoplasm. * patients with relapsed/refractory solid malignancy. * presence of primary or metastatic liver cancer. * history of a prior symptomatic venous thromboembolic event (vte) or arterial ischemic events. * patients with thrombocytopenia due to other etiologies e.g., underlying inherited thrombocytopenia.
patient outcome of cardiac surgery during the covid-19 pandemic

Conditions: Patients Undergoing Cardiac or Thoracic Surgery

Summary: this study will describe the recovery process of patients undergoing cardiac surgery during the covid-19 pandemic. this will focus on hemodynamic failure and organ dysfunction after surgery. capturing real-world data and sharing international experience will inform the management of this complex group of patients who undergo surgery throughout the covid-19 pandemic, improving their clinical care. this investigator-led, non-commercial, non-interventional does not collect any patient identifiable information.

performing cardiac surgery in the context of sars-cov2 infection is potentially at risk of marked post-operative hemodynamic failure (shock) due to the inflammatory reaction generated by the surgery and the extracorporeal circulation associated with the viral infection. in addition, in the absence of infection, 30-50% of patients will experience acute post-operative respiratory failure due to the combined effects of extracorporeal circulation and general anesthesia. the pulmonary tropism of the virus therefore is susceptible to increase in post-operative respiratory impairment. thus, the infection is likely to favor the occurrence of post-operative shock but also to aggravate respiratory failure and other post-operative organ failures. therefore, the investigators designed an observational study that aims at comparing two groups of patients: * cardiac or thoracic surgery patients with a negative covid-19 pcr pre-operatively and in the 15 following days * cardiac or thoracic surgery patients with a positive covid-19 pcr in the 15 days before surgery

Eligibility criteria:
inclusion criteria: * adults (age ≥18 years) undergoing cardiac or thoracic surgery * with positive pcr in the 5 days before or after cardiac/thoracic surgery. exclusion criteria: * minors

Keywords: cardiac surgery postoperative outcome covid-19 sars-cov 2 infection postoperative complication
mri guided radiation therapy for the treatment of high risk prostate cancer

Conditions: Prostate Adenocarcinoma; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8

Summary: this phase ii trial tests whether magnetic resonance imaging (mri)-guided hypofractionated radiation therapy works to reduce treatment time and side effects in patients with high risk prostate cancer. mri-guided hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time directly to diseased tissue, reducing damage to healthy tissue. using mri-guided radiation therapy on areas of the prostate and pelvic lymph nodes may shorten overall treatment time compared to the longer standard of care therapy and may reduce the number and/or duration of side effects.

primary objective: i. evaluate late grade 2+ genitourinary (gu) toxicity. secondary objective: i. evaluating acute gu and gastrointestinal (gi) toxicity, late gi toxicity, overall survival, prostate cancer specific survival, biochemical failure, and quality of life. outline: patients undergo mri-guided intensity-modulated radiation therapy (imrt) on study and receive standard of care (soc) antiandrogen therapy (adt) throughout the trial. patients may also undergo prostate specific membrane antigen (psma) positron emission tomography (pet), computed tomography (ct), mri, and bone scans at screening and undergo collection of blood samples throughout the trial. after completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for a total of 4 years.

Eligibility criteria:
inclusion criteria: * age: above 18 years * participants must be histologically proven, adenocarcinoma prostate * localized to the prostate without positive pelvic lymph node involvement * no distant metastatic disease assessed by pretreatment psma pet or bone scan and ct scan * high risk prostate cancer as defined by national comprehensive cancer network (nccn): gleason score of 8- 10, clinical stage t3a or higher, or prostate specific antigen (psa) \> 20 ng/ml * ability to receive long term hormone therapy * karnofsky performance score (kps) \> 70 * no prior history of therapeutic irradiation to pelvis * patient willing and reliable for follow-up and quality of life (qol) * english speaking/reading exclusion criteria: * evidence of distant or pelvic metastasis at any time since presentation * life expectancy \< 2 years * previous radiation therapy (rt) to prostate or prostatectomy * a previous trans-urethral resection of the prostate (turp) * severe urinary symptoms or with severe international prostate symptom score (ipss) score despite being on hormonal therapy for 6 months which in the opinion of the physician precludes rt * patients with known obstructive symptoms with stricture * any contraindication to radiotherapy such as inflammatory bowel disease